Telomir’s small molecule compound demonstrates potential in reversing cellular damage linked to oxidative stress and degenerative diseases.
Telomir Pharmaceuticals has announced results from preclinical trials of its small-molecule compound, Telomir-1 that reveal the molecule’s ability to fully reverse copper-induced oxidative stress in human cell lines and provide significant protection against cellular toxicity. These results could have significant implications for understanding and potentially treating age-related diseases and conditions exacerbated by oxidative stress.
Longevity.Technology: Telomeres, the protective caps at the ends of chromosomes, are critical for cellular health and longevity. As telomeres shorten with age, cells lose their ability to divide and repair effectively, and this process contributes to aging and increased vulnerability to oxidative stress – an imbalance between damaging free radicals and protective antioxidants. Oxidative stress is not only a driving force behind aging but also a critical factor in the development of diseases such as Alzheimer’s, cancer, cardiovascular disorders and diabetes; it also amplifies the severity of viral infections like avian influenza by triggering inflammation and cellular damage. Addressing oxidative stress is a key part of mitigating the progression of these diseases and their systemic effects.
A central factor in aging and disease
Telomir-1’s ability to normalize reactive oxygen species (ROS) levels represents a pivotal step in combating oxidative stress. Excess ROS, often produced in response to environmental stress or disease, damages cellular components such as DNA, lipids and proteins. This damage accelerates the progression of degenerative diseases, including Alzheimer’s and age-related macular degeneration (AMD), and contributes to the dysfunction of critical systems like the cardiovascular and nervous systems.
“The results of our studies demonstrate the exceptional potential of Telomir-1 in addressing oxidative stress and its related pathologies,” said Dr Raphael Mayer, CEO SmartAssays which helped to carry out the trial. “Telomir-1’s ability to fully normalize copper-induced ROS and to protect the cells from damage represents a significant leap forward in our understanding of this compound’s therapeutic potential.”
Telomir said that in preclinical trials, Telomir-1 demonstrated unique regulatory effects at doses far lower than those required for copper ion chelation, highlighting its potential beyond simple metal ion binding. According to the biotech, the compound’s ability to reverse ROS-induced damage holds promise for treating conditions such as Wilson’s disease, which involves toxic copper accumulation, and other diseases where copper dysregulation plays a role.
Implications for degenerative and metabolic diseases
Telomir-1’s applications could extend to several high-burden diseases. Alzheimer’s disease, characterized by neurodegeneration and cognitive decline, is driven in part by oxidative stress linked to protein misfolding and cellular damage. The compound’s potential to mitigate this damage offers hope for slowing disease progression. Similarly, AMD, a leading cause of blindness, could benefit from Telomir-1’s protective effects on retinal cells, addressing one of the primary drivers of vision loss.
“These findings underscore the unique profile of Telomir-1 as an intracellular regulator of oxidative stress,” said Dr Itzchak Angel, Chief Scientific Advisor at Telomir. “Its ability to act at low doses, rather than as a chelator, to reverse copper-induced ROS and toxicity positions it as a promising candidate for multiple indications, including neurodegeneration and metabolic disorders.”
The implications also extend to cancer and cardiovascular diseases, where oxidative stress contributes to tumor growth, DNA damage,and vascular dysfunction. Telomir-1’s regulatory capabilities could complement existing therapies by addressing the root causes of these conditions.
Exploring the connection between oxidative stress and viral infections
While the study focused primarily on degenerative diseases, Telomir Pharmaceuticals is also investigating Telomir-1’s potential in mitigating the effects of oxidative stress during viral infections, including avian influenza. Viral infections often exploit oxidative stress to enhance replication, leading to severe inflammation and tissue damage. The compound’s ability to reverse these effects could play a critical role in reducing the severity of outbreaks – something a post-pandemic world is likely to take note of.
Erez Aminov, CEO of Telomir, said: “With its unique regulatory mechanism and broad application, Telomir-1 is more than a single treatment – it is a platform that could potentially transform healthcare for millions. In addition to addressing age-related diseases, we are exploring its role in combating oxidative stress in viral infections such as avian influenza … Our mission is to leverage its capabilities to address unmet medical needs and improve patient outcomes worldwide.”
Looking forward
Although still in preclinical development, Telomir-1’s potential to address oxidative stress at a molecular level positions it as a promising candidate for tackling some of the most pressing health challenges associated with aging and disease. The company plans to advance its research toward clinical trials, exploring the compound’s applications in both degenerative diseases and viral infections.
